Snehal Patel, Jaye Thompson, F. Joseph Daugherty, François Clément Bidard, William John Gradishar, Miguel Martín, Joyce O'Shaughnessy, Hope S. Rugo, Cesar Augusto Santa-Maria, Marcus Schmidt, Laura Spring, Mothaffar Rimawi. "Preliminary injection site reaction immune response results from open-label arm of ongoing phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy (Flamingo-01).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.17_suppl.lba538